JP5943533B2 - 神経前駆細胞の集団 - Google Patents
神経前駆細胞の集団 Download PDFInfo
- Publication number
- JP5943533B2 JP5943533B2 JP2001585312A JP2001585312A JP5943533B2 JP 5943533 B2 JP5943533 B2 JP 5943533B2 JP 2001585312 A JP2001585312 A JP 2001585312A JP 2001585312 A JP2001585312 A JP 2001585312A JP 5943533 B2 JP5943533 B2 JP 5943533B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- differentiated
- neurons
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000005155 neural progenitor cell Anatomy 0.000 title claims description 54
- 210000004027 cell Anatomy 0.000 claims description 534
- 238000000034 method Methods 0.000 claims description 61
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 52
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 51
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 24
- 210000002242 embryoid body Anatomy 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 23
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 22
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 20
- 239000002858 neurotransmitter agent Substances 0.000 claims description 18
- 102000004230 Neurotrophin 3 Human genes 0.000 claims description 17
- 210000003169 central nervous system Anatomy 0.000 claims description 16
- 210000002950 fibroblast Anatomy 0.000 claims description 15
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 14
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 14
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 14
- 239000003102 growth factor Substances 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 13
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 12
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 11
- 229940116977 epidermal growth factor Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 10
- 102000004243 Tubulin Human genes 0.000 claims description 8
- 108090000704 Tubulin Proteins 0.000 claims description 8
- 208000036815 beta tubulin Diseases 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 7
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 230000007831 electrophysiology Effects 0.000 claims description 4
- 238000002001 electrophysiology Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000005495 thyroid hormone Substances 0.000 claims description 3
- 229940036555 thyroid hormone Drugs 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 230000004066 metabolic change Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 101150022753 galc gene Proteins 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 description 99
- 210000000130 stem cell Anatomy 0.000 description 61
- 239000002609 medium Substances 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 41
- 230000004069 differentiation Effects 0.000 description 39
- 230000001537 neural effect Effects 0.000 description 33
- 210000004498 neuroglial cell Anatomy 0.000 description 26
- 210000001130 astrocyte Anatomy 0.000 description 25
- 210000004248 oligodendroglia Anatomy 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 18
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 17
- 230000002518 glial effect Effects 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 16
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 16
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 16
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 16
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 16
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- 210000001671 embryonic stem cell Anatomy 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 229960001727 tretinoin Drugs 0.000 description 14
- 241000288906 Primates Species 0.000 description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 229930002330 retinoic acid Natural products 0.000 description 13
- 108010067306 Fibronectins Proteins 0.000 description 12
- 102000016359 Fibronectins Human genes 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 108010017842 Telomerase Proteins 0.000 description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000002459 blastocyst Anatomy 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102400001368 Epidermal growth factor Human genes 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000036982 action potential Effects 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 239000000411 inducer Substances 0.000 description 9
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000011591 potassium Substances 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 102000029816 Collagenase Human genes 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 7
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 7
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 7
- 108010085895 Laminin Proteins 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 6
- 102000007072 Nerve Growth Factors Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 238000004114 suspension culture Methods 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000004002 dopaminergic cell Anatomy 0.000 description 5
- 210000005064 dopaminergic neuron Anatomy 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 210000003061 neural cell Anatomy 0.000 description 5
- 210000001178 neural stem cell Anatomy 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 108090000031 Hedgehog Proteins Proteins 0.000 description 4
- 102000003693 Hedgehog Proteins Human genes 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 238000007877 drug screening Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000003900 neurotrophic factor Substances 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004874 Synaptophysin Human genes 0.000 description 3
- 108090001076 Synaptophysin Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- 210000000933 neural crest Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- -1 2 mM EDTA) Chemical compound 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002999 depolarising effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000044162 human IGF1 Human genes 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 230000000944 neurotransmitter response Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101000903318 Homo sapiens Stress-70 protein, mitochondrial Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100313320 Mus musculus Tert gene Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 238000012180 RNAeasy kit Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100022760 Stress-70 protein, mitochondrial Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000143 trophectoderm cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20560000P | 2000-05-17 | 2000-05-17 | |
| US60/205,600 | 2000-05-17 | ||
| US25760800P | 2000-12-22 | 2000-12-22 | |
| US60/257,608 | 2000-12-22 | ||
| PCT/US2001/015861 WO2001088104A2 (en) | 2000-05-17 | 2001-05-16 | Neural progenitor cell populations |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012260896A Division JP5685242B2 (ja) | 2000-05-17 | 2012-11-29 | 神経前駆細胞の集団 |
| JP2013268201A Division JP2014110790A (ja) | 2000-05-17 | 2013-12-26 | 神経前駆細胞の集団 |
| JP2016047121A Division JP2016146839A (ja) | 2000-05-17 | 2016-03-10 | 神経前駆細胞の集団 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003533224A JP2003533224A (ja) | 2003-11-11 |
| JP2003533224A5 JP2003533224A5 (https=) | 2008-05-29 |
| JP5943533B2 true JP5943533B2 (ja) | 2016-07-06 |
Family
ID=26900583
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001585312A Expired - Lifetime JP5943533B2 (ja) | 2000-05-17 | 2001-05-16 | 神経前駆細胞の集団 |
| JP2012260896A Expired - Fee Related JP5685242B2 (ja) | 2000-05-17 | 2012-11-29 | 神経前駆細胞の集団 |
| JP2013268201A Pending JP2014110790A (ja) | 2000-05-17 | 2013-12-26 | 神経前駆細胞の集団 |
| JP2016047121A Pending JP2016146839A (ja) | 2000-05-17 | 2016-03-10 | 神経前駆細胞の集団 |
| JP2017157484A Expired - Lifetime JP6644277B2 (ja) | 2000-05-17 | 2017-08-17 | 神経前駆細胞の集団 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012260896A Expired - Fee Related JP5685242B2 (ja) | 2000-05-17 | 2012-11-29 | 神経前駆細胞の集団 |
| JP2013268201A Pending JP2014110790A (ja) | 2000-05-17 | 2013-12-26 | 神経前駆細胞の集団 |
| JP2016047121A Pending JP2016146839A (ja) | 2000-05-17 | 2016-03-10 | 神経前駆細胞の集団 |
| JP2017157484A Expired - Lifetime JP6644277B2 (ja) | 2000-05-17 | 2017-08-17 | 神経前駆細胞の集団 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US20020009743A1 (https=) |
| EP (1) | EP1287116A2 (https=) |
| JP (5) | JP5943533B2 (https=) |
| KR (1) | KR100903755B1 (https=) |
| CN (1) | CN100580079C (https=) |
| AU (2) | AU6319901A (https=) |
| CA (1) | CA2409698C (https=) |
| GB (1) | GB2379447B (https=) |
| IL (2) | IL152741A0 (https=) |
| WO (1) | WO2001088104A2 (https=) |
Families Citing this family (211)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| ES2290032T3 (es) | 1999-05-03 | 2008-02-16 | Neuro Therapeutics Ab | Procedimiento para la produccion de neuronas dopaminergicas. |
| ATE319996T1 (de) * | 1999-12-16 | 2006-03-15 | Chugai Pharmaceutical Co Ltd | Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin |
| US20050042749A1 (en) | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
| US7011828B2 (en) * | 2000-03-14 | 2006-03-14 | Es Cell International Pte. Ltd. | Implanting neural progenitor cells derived for human embryonic stem cells |
| CA2403000C (en) | 2000-03-14 | 2015-06-23 | Es Cell International Pte Ltd | Embryonic stem cells and neural progenitor cells derived therefrom |
| JP5943533B2 (ja) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
| US7250294B2 (en) * | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| US6576464B2 (en) * | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
| US6921665B2 (en) | 2000-11-27 | 2005-07-26 | Roslin Institute (Edinburgh) | Selective antibody targeting of undifferentiated stem cells |
| JP3763749B2 (ja) * | 2001-03-28 | 2006-04-05 | 独立行政法人科学技術振興機構 | 脊髄におけるシナプス形成ニューロンを誘導する中枢神経系前駆細胞 |
| US7943376B2 (en) | 2001-04-27 | 2011-05-17 | Stem Cell Therapuetics Inc. | Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells |
| CN101029302B (zh) * | 2001-06-21 | 2011-03-30 | 杰龙公司 | 用于治疗帕金森病的多巴胺能神经元和具有增殖能力的前体细胞 |
| JP3886346B2 (ja) * | 2001-06-22 | 2007-02-28 | サンバイオ，インコーポレイティド | 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物 |
| DE10134667A1 (de) * | 2001-07-20 | 2003-02-06 | Neuroprogen Gmbh Leipzig | Verfahren zur Herstellung isolierter Zellkulturen, Kulturmedium zur Kultivierung von Zellkulturen und Zellkultur |
| US7588937B2 (en) | 2001-10-03 | 2009-09-15 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
| US8153424B2 (en) * | 2001-10-03 | 2012-04-10 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
| US6887706B2 (en) | 2001-10-03 | 2005-05-03 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells |
| US7129034B2 (en) * | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
| US20030153082A1 (en) | 2001-12-07 | 2003-08-14 | The John P. Robarts Research Institute | Hematopoietic cells from human embryonic stem cells |
| CA2473115A1 (en) * | 2002-01-09 | 2003-07-24 | Japan Science And Technology Agency | Remedy for dysmnesia |
| EP1471970A4 (en) | 2002-01-14 | 2006-08-02 | Univ Illinois | NOVEL MULTIPOTENT STEM CELLS OF MAMMALIAN ORIGIN, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION OF SAID CELLS |
| KR20040075957A (ko) * | 2002-01-23 | 2004-08-30 | 유니버시티 오브 유타 리서치 파운데이션 | 별아교세포 제한 전구체 세포의 순수한 집단과 그것을분리하고 이용하는 방법 |
| EP1499180A4 (en) * | 2002-04-16 | 2006-09-13 | Dana Farber Cancer Inst Inc | CANCER MODELS |
| WO2003104444A1 (en) | 2002-06-05 | 2003-12-18 | Es Cell International Pte Ltd | Generation of neural stem cells from undifferentiated human embryonic stem cells |
| AU2003229132B9 (en) * | 2002-06-05 | 2009-07-23 | Es Cell International Pte Ltd | Generation of neural stem cells from undifferentiated human embryonic stem cells |
| US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US20050101014A1 (en) | 2002-07-11 | 2005-05-12 | Keirstead Hans S. | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US7632679B2 (en) * | 2002-07-16 | 2009-12-15 | The Trustees Of Columbia University In The City Of New York | Systems and methods for screening for modulators of neural differentiation |
| US20040224302A1 (en) * | 2002-07-16 | 2004-11-11 | Thomas Jessel | Systems and methods for screening for modulators of neural differentiation |
| US20060233771A1 (en) * | 2002-09-24 | 2006-10-19 | Ernesto Arenas | Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands |
| AU2003276924A1 (en) * | 2002-09-25 | 2004-04-19 | Bresagen, Inc. | Compositions and methods for enrichment of neural stem cells using ceramide analogs |
| US20040147020A1 (en) * | 2002-11-01 | 2004-07-29 | The Regents Of The University Of Colorado, A Body Corporate | Dopamine neurons from human embryonic stem cells |
| US20050265983A1 (en) * | 2002-11-17 | 2005-12-01 | Eldad Melamed | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
| AU2003293409A1 (en) * | 2002-12-09 | 2004-06-30 | Karl K. Johe | Method for discovering neurogenic agents |
| ES2705683T3 (es) | 2002-12-16 | 2019-03-26 | Technion Res & Dev Foundation | Medio de cultivo de células madre pluripotentes |
| US20060211111A1 (en) * | 2002-12-18 | 2006-09-21 | Maisam Mitalipova | Compositions and methods for neural cell production and stabilization |
| US8642332B2 (en) * | 2003-03-07 | 2014-02-04 | Cornell Research Foundation, Inc. | Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain |
| ZA200401646B (en) * | 2003-03-12 | 2004-06-07 | Reliance Life Sciences Pvt Ltd | Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells. |
| WO2004081172A2 (en) * | 2003-03-12 | 2004-09-23 | Reliance Life Sciences Pvt. Ltd. | Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells |
| US7153650B2 (en) | 2003-03-13 | 2006-12-26 | Geron Corporation | Marker system for preparing and characterizing high-quality human embryonic stem cells |
| US20060183221A1 (en) * | 2003-03-31 | 2006-08-17 | Schulz Thomas C | Method for neural differentiation of embryonic stem cells using protease passaging techniques |
| WO2004099395A2 (en) * | 2003-05-08 | 2004-11-18 | Cellartis Ab | A method for the generation of neural progenitor cells |
| WO2006040615A2 (en) * | 2003-06-11 | 2006-04-20 | Jan Remmereit | Differenciation of stem cells for therapeutic use |
| AU2004247961B2 (en) * | 2003-06-12 | 2010-06-24 | Yeda Research & Development Co.Ltd | Enhancement of oligodendrocyte differentiation |
| EP1670901A4 (en) * | 2003-08-29 | 2007-09-05 | Wisconsin Alumni Res Found | METHOD FOR IN VITRO DIFFERENTIATION OF NEURAL STEM CELLS, MOTOR NEURONES AND DOPAMINE NEURONES FROM EMBRYONAL PRIMATIVE STEM CELLS |
| US7820439B2 (en) | 2003-09-03 | 2010-10-26 | Reliance Life Sciences Pvt Ltd. | In vitro generation of GABAergic neurons from pluripotent stem cells |
| WO2005030932A2 (en) * | 2003-09-24 | 2005-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Igf-1 instructs multipotent adult cns neural stem cells to an oligodendroglial lineage |
| US20070269412A1 (en) * | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
| WO2005063972A1 (en) | 2003-12-30 | 2005-07-14 | Seoul National University Industry Foundation | Embryonic stem cell line and method for preparing the same |
| WO2005079250A2 (en) * | 2004-02-13 | 2005-09-01 | Cornell Research Foundation, Inc. | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom |
| JP5226928B2 (ja) * | 2004-04-16 | 2013-07-03 | 株式会社カネカ | 細胞の分化転換方法 |
| US20050272149A1 (en) * | 2004-06-02 | 2005-12-08 | Life & Brain Gmbh | Therapeutic delivery of adenosine into a tissue |
| CA2569978C (en) | 2004-06-09 | 2017-06-06 | The University Court Of The University Of Edinburgh | Neural stem cells |
| WO2006017370A2 (en) | 2004-07-13 | 2006-02-16 | Geron Corporation | Medium for growing human embryonic stem cells |
| EP1786471B1 (en) | 2004-07-30 | 2015-02-11 | Mayo Foundation For Medical Education And Research | Treating cardiovascular tissue |
| EP1786921B1 (en) | 2004-08-12 | 2011-01-12 | Neuro Probe, Inc. | Point source diffusion cell activity assay apparatuses and methods |
| US20060040389A1 (en) * | 2004-08-17 | 2006-02-23 | Murry Charles E | Purified compositions of stem cell derived differentiating cells |
| TW200617165A (en) * | 2004-09-06 | 2006-06-01 | Tanabe Seiyaku Co | Process for preparing a conditioned medium of astrocyte-like cells |
| CA2583473A1 (en) * | 2004-10-05 | 2007-04-04 | University Of Georgia Research Foundation, Inc. | Neuronal progenitors from feeder-free human embryonic stem cell culture |
| US8192988B2 (en) | 2004-10-22 | 2012-06-05 | University Of Central Florida Research Foundation, Inc. | Methods for increasing potency of adult mesenchymal stem cells |
| EP1831354A4 (en) * | 2004-12-01 | 2008-01-23 | Stem Cell Therapeutics Corp | NEURAL PRECURSOR CELLS SENSITIVE TO PLATELET GROWTH FACTOR AND PROHIBITION OF SAID CELLS |
| EP1844139A1 (en) * | 2004-12-30 | 2007-10-17 | Stemlifeline, Inc. | Methods and systems relating to embryonic stem cell lines |
| US20060275899A1 (en) * | 2004-12-30 | 2006-12-07 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
| WO2006072005A2 (en) * | 2004-12-30 | 2006-07-06 | The Johns Hopkins University | Methods for high efficiency survival/proliferation of human embyonic stem cells and human embyro survival in culture |
| EP1856248A4 (en) * | 2005-02-09 | 2010-01-20 | Burnham Inst Medical Research | HOMOGENEOUS NEURALE CURRENT CELLS |
| PT1855700E (pt) | 2005-03-07 | 2013-12-10 | Sanbio Inc | Utilização de materiais para tratamento de lesões do sistema nervoso central |
| EP1893747B1 (en) | 2005-06-16 | 2014-09-03 | Ramot at Tel Aviv University Ltd. | Isolated cells and populations comprising same for the treatment of cns diseases |
| US20060292694A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Reporter hepatocytes and other cells for drug screening and toxicity testing |
| EP1893749A1 (en) * | 2005-06-22 | 2008-03-05 | Geron Corporation | Reporter hepatocytes and other cells for drug screening and toxicity testing |
| KR20160116024A (ko) * | 2005-06-22 | 2016-10-06 | 아스테리아스 바이오세라퓨틱스, 인크. | 인간 배아 줄기 세포의 현탁 배양 |
| US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
| AU2006269231A1 (en) * | 2005-07-08 | 2007-01-18 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
| CN101351544B (zh) * | 2005-08-26 | 2013-06-12 | 罗切斯特大学 | 胶质限制性前体衍生的星形胶质细胞移植以促进轴突生长 |
| WO2007026353A2 (en) | 2005-08-29 | 2007-03-08 | Technion Research & Development Foundation Ltd. | Media for culturing stem cells |
| BRPI0617085A2 (pt) | 2005-09-02 | 2016-11-08 | Agency Science Tech & Res | método para obter uma célula-tronco mesenquimal (msc), célula ou linhagem celular, método para derivar uma cultura celular a partir de uma célula-tronco embrionária, método para tratamento de uma doença, uso de uma célula-tronco mesenquimal, linhagem diferenciada, composição farmacêutica, método para condicionar um meio de cultura celular, meio condicionado e uso do mesmo, mpetodo para obterum polipeptídeo, método para obtar uma cultura celular, cultura celular, célula-tronco mesenquimal, linhagem de célula-tronco mesenquimal ou uma célula mesenquimal diferenciada |
| CN101374537B (zh) | 2005-11-10 | 2016-04-20 | 健能万生物制药公司 | 干细胞的mntf分化和生长 |
| WO2007066338A1 (en) * | 2005-12-08 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases |
| BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| KR100683199B1 (ko) | 2006-01-09 | 2007-02-15 | 주식회사 휴림바이오셀 | 신경전구세포를 콜린성 신경세포로 분화시키는 방법 및그에 사용되는 배지 |
| KR100683198B1 (ko) | 2006-01-09 | 2007-02-15 | 주식회사 휴림바이오셀 | 신경전구세포를 도파민성 신경세포로 분화시키는 방법 및그에 사용되는 배지 |
| WO2007091790A1 (en) * | 2006-02-07 | 2007-08-16 | Korea Institute Of Radiological & Medical Sciences | A composition for treating damage of central or peripheral nerve system |
| KR100838013B1 (ko) * | 2006-06-07 | 2008-06-12 | 제일약품주식회사 | 인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법 |
| US20080003676A1 (en) * | 2006-06-26 | 2008-01-03 | Millipore Corporation | Growth of embryonic stem cells |
| US9765298B2 (en) * | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
| EP2059586B1 (en) | 2006-08-02 | 2016-07-20 | Technion Research & Development Foundation Ltd. | Methods of expanding embryonic stem cells in a suspension culture |
| WO2008100168A1 (en) * | 2007-02-16 | 2008-08-21 | Universidade De Coimbra | Method for the functional identification of new neurons, neural progenitors, astrocytes and immature cells from stem cell cultures and uses thereof |
| WO2008127974A1 (en) * | 2007-04-13 | 2008-10-23 | The Trustees Of Columbia University In The City Of New York | Stem cell-based culture system for drug development |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| WO2008156708A2 (en) * | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Methods and compositions for enhanced differentiation from embryonic stem cells |
| EP2185694A2 (en) | 2007-08-02 | 2010-05-19 | California Stem Cell, Inc. | Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells |
| KR100941036B1 (ko) | 2007-10-05 | 2010-02-05 | 고려대학교 산학협력단 | 인간 배아줄기세포로부터 척수신경계 희소돌기 아교세포생산을 위한 삼단계 분화기법 |
| WO2009066817A1 (en) * | 2007-11-23 | 2009-05-28 | Seoul National University Industry Foundation | Method for inducing differentiation of human mesenchymal stem cells into motor neurons |
| CA2714010C (en) | 2008-01-30 | 2020-06-16 | Corning Incorporated | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| SG10201400329YA (en) | 2008-05-02 | 2014-05-29 | Univ Kyoto | Method of nuclear reprogramming |
| WO2009145761A1 (en) * | 2008-05-27 | 2009-12-03 | Mayo Foundation For Medical Education And Research | Methods and materials for using cells to treat heart tissue |
| EP2620493B1 (en) | 2008-05-28 | 2019-03-27 | Ramot at Tel Aviv University Ltd. | Mesenchymal stem cells for the treatment of CNS diseases |
| US8969081B2 (en) * | 2008-12-10 | 2015-03-03 | The Trustees Of Columbia University In The City Of New York | Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid |
| US20100158878A1 (en) | 2008-12-23 | 2010-06-24 | Alexandra Capela | Target populations of oligodendrocyte precursor cells and methods of making and using same |
| US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
| US8642334B2 (en) | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| CN102803472B (zh) | 2009-06-25 | 2014-04-23 | 吉隆公司 | 去除了外来表型的由多能干细胞分化的子代细胞 |
| WO2011005326A1 (en) | 2009-07-09 | 2011-01-13 | Massachusetts Institute Of Technology | Methods and compositions for increased safety of stem cell-derived populations |
| US11261425B2 (en) | 2009-08-12 | 2022-03-01 | Kyoto University | Method for inducing differentiation of pluripotent stem cells into neural precursor cells |
| CN102597218B (zh) * | 2009-08-12 | 2017-10-27 | 国立大学法人京都大学 | 用于诱导多能干细胞分化成神经前体细胞的方法 |
| US20120244567A1 (en) * | 2009-09-04 | 2012-09-27 | Buck Institute For Research On Aging | Human embryonic stem cells for high throughout drug screening |
| EP2490701B9 (en) | 2009-10-19 | 2017-11-15 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| WO2011059920A2 (en) | 2009-11-10 | 2011-05-19 | The J. David Gladstone Institutes | Methods of generating neural stem cells |
| EP3633025B1 (en) | 2009-11-12 | 2022-09-14 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| US10485829B2 (en) | 2009-11-17 | 2019-11-26 | Astellas Institute For Regenerative Medicine | Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells |
| EP2507363A4 (en) * | 2009-12-02 | 2013-10-30 | Res Dev Foundation | SELECTION OF STEM CELL CLONES WITH DEFINED DIFFERENTIATION POSSIBILITIES |
| CA2796251C (en) | 2010-04-13 | 2019-05-14 | Cellular Dynamics International, Inc. | Hepatocyte production by forward programming |
| WO2011133661A2 (en) | 2010-04-21 | 2011-10-27 | Research Development Foundation | Methods and compositions related to dopaminergic neuronal cells |
| CA2802087A1 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
| CA2802525C (en) | 2010-06-18 | 2021-06-22 | Cellular Dynamics International, Inc. | Cardiomyocyte medium with dialyzed serum |
| WO2012006440A2 (en) | 2010-07-07 | 2012-01-12 | Cellular Dynamics International, Inc. | Endothelial cell production by programming |
| AU2011279250B2 (en) | 2010-07-12 | 2014-12-04 | California Institute Of Technology | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
| US20130108589A1 (en) * | 2010-07-22 | 2013-05-02 | Affiliated Hospital Of Ningxia Medical University | Method of Producing Neurons from Stem Cells, the Neurons and Uses Thereof |
| WO2012013936A1 (en) * | 2010-07-30 | 2012-02-02 | Cambridge Enterprise Limited | Corticogenesis of human pluripotent cells |
| WO2012018933A2 (en) | 2010-08-04 | 2012-02-09 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| WO2012061741A2 (en) * | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University. | Control and characterization of psychotic states |
| TWI586805B (zh) * | 2011-01-12 | 2017-06-11 | 城戶常雄 | 獲得及維持在體外易於分化為寡樹突細胞－族系細胞之哺乳類神經幹細胞及／或神經祖源細胞的純或增富族群之培養方法 |
| WO2012109208A2 (en) | 2011-02-08 | 2012-08-16 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
| US20140051085A1 (en) * | 2011-03-01 | 2014-02-20 | The Scripps Research Institute | Direct reprogramming of human fibroblasts to functional neurons under defined conditions |
| US20140329314A1 (en) | 2011-03-29 | 2014-11-06 | Christopher O'Sullivan | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
| JP6185907B2 (ja) | 2011-03-30 | 2017-08-23 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 神経分化のための多能性幹細胞の予備刺激 |
| US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
| US10478206B2 (en) | 2011-04-29 | 2019-11-19 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
| WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
| CN102899285A (zh) * | 2011-07-29 | 2013-01-30 | 复旦大学 | 一种体外诱导胚胎干细胞分化成为神经细胞方法 |
| CA2841985C (en) | 2011-07-29 | 2019-09-17 | Cellular Dynamics International, Inc. | Metabolic maturation in stem cell-derived tissue cells |
| PT2773748T (pt) | 2011-11-04 | 2020-03-26 | Memorial Sloan Kettering Cancer Center | Neurónios dopaminérgicos (da) do mesencéfalo para enxerto |
| US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
| US9447378B2 (en) | 2012-04-27 | 2016-09-20 | Massachusetts Institute Of Technology | Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes |
| SG11201505152PA (en) | 2012-12-28 | 2015-08-28 | Univ Kyoto | Method for inducing astrocytes |
| EP2954046B1 (en) * | 2013-02-06 | 2025-10-15 | University Of Rochester | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders |
| CN105229144A (zh) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | 通过组合的遗传工程和化学工程经由正向编程产生肝细胞 |
| CN105431522B (zh) | 2013-03-14 | 2021-08-03 | 加利福尼亚大学董事会 | 内侧神经节隆起前体细胞的体外产生 |
| US10266807B2 (en) | 2013-04-03 | 2019-04-23 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| EP3498824A1 (en) | 2013-04-26 | 2019-06-19 | Memorial Sloan-Kettering Cancer Center | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
| WO2014200340A1 (en) | 2013-06-10 | 2014-12-18 | Academisch Ziekenhuis Leiden | Differentiation and expansion of endothelial cells from pluripotent stem cells and the in vitro formation of vasculature like structures |
| SG11201510177WA (en) | 2013-06-11 | 2016-01-28 | Harvard College | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME |
| US9816070B2 (en) | 2013-06-14 | 2017-11-14 | Massachusetts Institute Of Technology | Articles and methods for stem cell differentiation |
| AU2014316100B2 (en) * | 2013-09-05 | 2020-11-05 | Eisai R&D Management Co., Ltd. | New method for inducing dopamine-producing neural precursor cells |
| CN105814196A (zh) * | 2013-10-14 | 2016-07-27 | 哈达斯特医疗研究服务和开发有限公司 | 终末分化的神经元谱系的获得方法及其用途 |
| JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| JP6723918B2 (ja) | 2013-11-21 | 2020-07-15 | メモリアル スローン ケタリング キャンサー センター | ヒト多能性幹細胞からの機能的頭蓋プラコード派生体の特定 |
| WO2015143342A1 (en) | 2014-03-21 | 2015-09-24 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| EP3134515B1 (en) | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| EP3174975B1 (en) * | 2014-07-31 | 2020-09-16 | Université d'Aix-Marseille | Method for generating neuronal and muscular cells |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| EP3207122B1 (en) | 2014-10-14 | 2019-05-08 | FUJIFILM Cellular Dynamics, Inc. | Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures |
| CN105624116B (zh) * | 2014-11-07 | 2020-04-07 | 中国科学院上海生命科学研究院 | 利用多能干细胞制备神经前体细胞的方法 |
| WO2016100909A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
| WO2016100898A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof |
| CN107614678B (zh) | 2014-12-18 | 2021-04-30 | 哈佛学院校长同事会 | 干细胞来源的β细胞的产生方法及其使用方法 |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| DK3303564T3 (da) * | 2015-06-01 | 2022-04-04 | Memorial Sloan Kettering Cancer Center | Fremgangsmåder til in vitro-differentiering af midthjerne-dopamin-(mda)-neuroner |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US10384207B2 (en) | 2015-07-21 | 2019-08-20 | Neuro Probe Incorporated | Assay apparatus and methods |
| CN114807035B (zh) | 2015-09-08 | 2024-02-02 | (由卫生与公众服务部部长代表的)美利坚合众国 | 临床级别视网膜色素上皮细胞的可再现的分化方法 |
| KR20260003355A (ko) | 2015-09-08 | 2026-01-06 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 줄기 세포에서 유래된 망막색소상피의 macs 기반 정제 |
| AU2016335563B2 (en) | 2015-10-08 | 2022-10-27 | Neurona Therapeutics Inc. | Neural precursor cell populations and uses thereof |
| MX2018005274A (es) | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. |
| CN116121189A (zh) * | 2016-03-30 | 2023-05-16 | 阿斯特利亚斯生物治疗股份公司 | 少突胶质细胞祖细胞组合物 |
| JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
| JP7471084B2 (ja) * | 2017-03-21 | 2024-04-19 | メモリアル スローン ケタリング キャンサー センター | 幹細胞由来星状細胞、作製方法および使用方法 |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| JP7457505B2 (ja) | 2017-05-10 | 2024-03-28 | ユニバーシティー オブ ロチェスター | 神経精神障害を処置する方法 |
| KR20250048146A (ko) | 2017-11-15 | 2025-04-07 | 셈마 테라퓨틱스, 인크. | 섬세포 제조 조성물 및 사용 방법 |
| KR102920569B1 (ko) | 2018-04-20 | 2026-02-02 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 안구 세포의 분화를 위한 방법 및 이의 용도 |
| RU2690846C1 (ru) * | 2018-05-17 | 2019-06-06 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" | Ноотропная композиция на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека |
| RU2690498C1 (ru) * | 2018-05-17 | 2019-06-04 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" | Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека |
| WO2020033879A1 (en) | 2018-08-10 | 2020-02-13 | Semma Therapeutics, Inc. | Stem cell derived islet differentiation |
| IL281628B2 (en) | 2018-09-19 | 2025-06-01 | Lineage Cell Therapeutics Inc | Methods for differentiating pluripotent stem cells in dynamic suspension culture |
| AU2019385332B2 (en) | 2018-11-19 | 2025-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biodegradable tissue replacement implant and its use |
| KR20200077222A (ko) | 2018-12-20 | 2020-06-30 | (주)영인바이오텍 | 통증완화부를 가지는 회복 운동 장치 |
| KR20200077218A (ko) | 2018-12-20 | 2020-06-30 | (주)영인바이오텍 | 교체가능한 부품을 가지는 회복 운동 장치 |
| CN113439120B (zh) * | 2019-01-22 | 2025-02-14 | 高丽大学校产学协力团 | 用于将神经干细胞分化为星形胶质细胞的基于直接细胞转化的方法 |
| KR20220039647A (ko) * | 2019-04-03 | 2022-03-29 | 더 존스 홉킨스 유니버시티 | 골격근 줄기세포 생성 및 질환 치료를 위한 방법, 조성물 및 키트 |
| ES2960527T3 (es) | 2019-09-13 | 2024-03-05 | Miltenyi Biotec Bv & Co Kg | Método para la generación de una composición celular de células progenitoras dopaminérgicas del mesencéfalo ventral |
| WO2021097346A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Hematopoietic precursor cell production |
| JP2023502785A (ja) * | 2019-11-25 | 2023-01-25 | ザ・ペン・ステイト・リサーチ・ファウンデイション | ヒトグリア細胞をニューロンに変換するための組成物および方法 |
| RU2752906C2 (ru) * | 2019-12-26 | 2021-08-11 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" | Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях теплового шока, и способ ее получения |
| RU2732600C1 (ru) * | 2019-12-26 | 2020-09-21 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" | Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях гипоксии, и способ ее получения |
| RU2732599C1 (ru) * | 2019-12-26 | 2020-09-21 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" | Ноотропная композиция на основе полипептидных комплексов, выделенных из глиальных прогениторных клеток в условиях теплового шока, и способ её получения |
| GB202006792D0 (en) * | 2020-05-07 | 2020-06-24 | Ericson Lars Johan | Method and uses thereof |
| BR112022024031A2 (pt) | 2020-05-29 | 2023-01-31 | Fujifilm Cellular Dynamics Inc | Agregados de células duplas de epitélio pigmentado da retina e fotorreceptor, e métodos de uso dos mesmos |
| CA3180561A1 (en) | 2020-05-29 | 2021-12-02 | Andrew DIAS | Bilayer of retinal pigmented epithelium and photoreceptors and use thereof |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| CA3213988A1 (en) | 2021-04-07 | 2022-10-13 | Christopher MCMAHON | Dopaminergic precursor cells and methods of use |
| WO2022251499A1 (en) | 2021-05-28 | 2022-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to generate macular, central and peripheral retinal pigment epithelial cells |
| WO2022251477A1 (en) | 2021-05-28 | 2022-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells |
| US12152699B2 (en) | 2022-02-28 | 2024-11-26 | Terumo Bct, Inc. | Multiple-tube pinch valve assembly |
| CN116478923B (zh) * | 2022-04-26 | 2024-01-02 | 浙江霍德生物工程有限公司 | 一种星形胶质细胞的制备方法 |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| WO2025090879A1 (en) | 2023-10-26 | 2025-05-01 | Amgen Inc. | Pluripotent cell differentiation |
| US20250362218A1 (en) | 2024-05-21 | 2025-11-27 | FUJIFILM Cellular Dynamics, Inc. | Particle counting and biomass measurements of aggregated cell compositions |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2198403T3 (es) | 1991-06-18 | 2004-02-01 | Osiris Therapeutics, Inc. | Celulas madre mesenquimaticas humanas derivadas de medula y anticuerpos monoclonales especificos para dichas celulas. |
| DE69232535D1 (de) | 1991-06-24 | 2002-05-08 | Pacific Biomedical Res Inc | In langzeitkultur gehaltene hormon-absondernde pankreatische zellen |
| US5981165A (en) | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
| US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
| ES2198404T5 (es) | 1991-07-08 | 2008-05-01 | Neurospheres Holdings Ltd. | Celulas progenitoras neurales que responden a factor de crecimiento y que se pueden hacer proliferar in vitro. |
| AU667680B2 (en) | 1991-08-07 | 1996-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Proliferation of hepatocyte precursors |
| US5928947A (en) | 1992-07-27 | 1999-07-27 | California Institute Of Technology | Mammalian multipotent neural stem cells |
| US5849553A (en) | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
| AU4995193A (en) | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
| US5766948A (en) | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
| US5534404A (en) | 1993-12-10 | 1996-07-09 | Cytotherapeutics, Inc. | Glucose responsive insulin secreting β-cell lines and method for producing same |
| US5639618A (en) | 1994-05-13 | 1997-06-17 | Plurion, Inc. | Method of isolating a lineage specific stem cell in vitro |
| US5476975A (en) | 1994-07-08 | 1995-12-19 | Ruddick; John N. R. | Extraction of toxic organic contaminants from wood and photodegradation of toxic organic contaminants |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| GB9807935D0 (en) * | 1998-04-14 | 1998-06-10 | Univ Edinburgh | Lineage specific cells and progenitor cells |
| US5753506A (en) | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
| US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| US6361996B1 (en) * | 1997-05-07 | 2002-03-26 | University Of Utah Research Foundation | Neuroepithelial stem cells and glial-restricted intermediate precursors |
| US6235527B1 (en) | 1997-11-29 | 2001-05-22 | University Of Utah Research Foundation | Lineage restricted glial precursors from the central nervous system |
| AU755657B2 (en) * | 1997-07-04 | 2002-12-19 | University Of Utah Research Foundation | Lineage-restricted neuronal precursors |
| US7144997B2 (en) | 1997-07-24 | 2006-12-05 | Curis, Inc. | Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| AU729377B2 (en) | 1997-10-23 | 2001-02-01 | Asterias Biotherapeutics, Inc. | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
| DE19756864C5 (de) * | 1997-12-19 | 2014-07-10 | Oliver Brüstle | Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten |
| WO1999043785A1 (en) | 1998-02-27 | 1999-09-02 | Medical College Of Hampton Roads | Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies |
| EP1068295A4 (en) | 1998-04-09 | 2002-08-21 | Bresagen Ltd | CELL DIFFERENTIATION / PROLIFERATION AND CONSERVATION FACTOR AND METHODS OF USE THEREOF |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| DE19843234A1 (de) * | 1998-09-09 | 2000-03-23 | Inst Pflanzengenetik & Kultur | Differenzierte Herzzellen mit pathologischen Merkmalen als in vitro-Modell für Herzerkrankungen |
| WO2000017323A1 (en) | 1998-09-22 | 2000-03-30 | Neuralstem Biopharmaceuticals, Ltd. | Stable neural stem cell lines |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6087168A (en) | 1999-01-20 | 2000-07-11 | Cedars Sinai Medical Center | Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells |
| AU780256B2 (en) | 1999-02-12 | 2005-03-10 | Boco Silicon Valley, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US6238922B1 (en) | 1999-02-26 | 2001-05-29 | Stemcells, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
| JP2002538820A (ja) | 1999-03-17 | 2002-11-19 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション | ミクロクローンのクローニングされていないｃＤＮＡライブラリーの作製および使用 |
| CN1362965A (zh) | 1999-06-30 | 2002-08-07 | 先进细胞技术公司 | 细胞质转移使受体细胞去分化 |
| AU2913801A (en) | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| US20050042749A1 (en) * | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
| US6602711B1 (en) | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
| CA2403000C (en) * | 2000-03-14 | 2015-06-23 | Es Cell International Pte Ltd | Embryonic stem cells and neural progenitor cells derived therefrom |
| US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
| AU2001259323A1 (en) | 2000-05-01 | 2001-11-12 | Sang-Hun Lee | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
| US8273570B2 (en) | 2000-05-16 | 2012-09-25 | Riken | Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells |
| JP5943533B2 (ja) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
| US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| WO2001098463A1 (en) | 2000-06-20 | 2001-12-27 | Es Cell International Pte Ltd | Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists |
| JP3660601B2 (ja) | 2001-03-30 | 2005-06-15 | 独立行政法人科学技術振興機構 | 胚性幹細胞からの神経幹細胞、運動ニューロン及びｇａｂａ作動性ニューロンの製造法 |
| EP1385938A1 (en) | 2001-04-23 | 2004-02-04 | Nsgene A/S | Method and culture medium for producing neural cells expressing tyrosine hydroxylase |
| US20030113910A1 (en) | 2001-12-18 | 2003-06-19 | Mike Levanduski | Pluripotent stem cells derived without the use of embryos or fetal tissue |
| US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| EP1831354A4 (en) * | 2004-12-01 | 2008-01-23 | Stem Cell Therapeutics Corp | NEURAL PRECURSOR CELLS SENSITIVE TO PLATELET GROWTH FACTOR AND PROHIBITION OF SAID CELLS |
-
2001
- 2001-05-16 JP JP2001585312A patent/JP5943533B2/ja not_active Expired - Lifetime
- 2001-05-16 KR KR1020027015192A patent/KR100903755B1/ko not_active Expired - Fee Related
- 2001-05-16 EP EP01937463A patent/EP1287116A2/en not_active Withdrawn
- 2001-05-16 CA CA2409698A patent/CA2409698C/en not_active Expired - Lifetime
- 2001-05-16 WO PCT/US2001/015861 patent/WO2001088104A2/en not_active Ceased
- 2001-05-16 US US09/859,351 patent/US20020009743A1/en not_active Abandoned
- 2001-05-16 GB GB0229369A patent/GB2379447B/en not_active Expired - Lifetime
- 2001-05-16 CN CN01809662A patent/CN100580079C/zh not_active Expired - Fee Related
- 2001-05-16 IL IL15274101A patent/IL152741A0/xx active IP Right Grant
- 2001-05-16 AU AU6319901A patent/AU6319901A/xx active Pending
- 2001-05-16 AU AU2001263199A patent/AU2001263199B2/en not_active Expired
- 2001-05-31 US US09/872,183 patent/US6833269B2/en not_active Expired - Lifetime
-
2002
- 2002-11-10 IL IL152741A patent/IL152741A/en unknown
-
2005
- 2005-11-16 US US11/281,040 patent/US8148148B2/en not_active Expired - Fee Related
-
2008
- 2008-12-11 US US12/332,783 patent/US8252585B2/en not_active Expired - Fee Related
-
2012
- 2012-07-25 US US13/558,078 patent/US9803174B2/en not_active Expired - Fee Related
- 2012-11-29 JP JP2012260896A patent/JP5685242B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-26 JP JP2013268201A patent/JP2014110790A/ja active Pending
-
2014
- 2014-03-18 US US14/217,699 patent/US20140242691A1/en not_active Abandoned
-
2016
- 2016-03-10 JP JP2016047121A patent/JP2016146839A/ja active Pending
-
2017
- 2017-08-17 JP JP2017157484A patent/JP6644277B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5943533B2 (ja) | 神経前駆細胞の集団 | |
| JP4526265B2 (ja) | パーキンソン病を治療するためのドーパミン作動性ニューロンおよび増殖能のある前駆細胞 | |
| AU2001263199A1 (en) | Neural progenitor cell populations | |
| JP5159804B2 (ja) | パーキンソン病を治療するためのドーパミン作動性ニューロンおよび増殖能のある前駆細胞 | |
| US7763463B2 (en) | Use of cyclic AMP and ascorbic acid to produce dopaminergic neurons from embryonic stem cells | |
| AU2004214542B2 (en) | Neural progenitor cell populations | |
| HK1055765B (en) | Neural progenitor cell populations | |
| HK1075673B (en) | Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080403 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080403 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080403 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110324 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110623 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110914 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120531 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120626 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121129 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130826 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140108 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20140512 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140627 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150702 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150806 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150909 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151013 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160310 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151013 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160524 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5943533 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |